Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Sareum Holdings plc
  6. News
  7. Summary
    SAR   GB00B02RFS12

SAREUM HOLDINGS PLC

(SAR)
  Report
Delayed Quote. Delayed London Stock Exchange - 09/24 11:35:04 am
6.75 GBX   +1.50%
07/30SAREUM : Shares Jump 8% on Incoming Cancer Treatment Patent
MT
07/30SAREUM : Patent Notice of Allowance for SDC-1802
PU
07/21Sareum Holdings plc Provides Financial Guidance for Fiscal 2021
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Sareum : Exercise of Options and TVR

05/13/2021 | 11:04am EDT

SAREUM HOLDINGS PLC

('Sareum' or the 'Company')

Exercise of Options and Total Voting Rights

Sareum Holdings plc (AIM: SAR)announces that it has received notice of exercise of share options from a consultant to the Company over 3,000,000 new ordinary shares of 0.25 pence each in the capital of the Company ('Ordinary Shares') at an exercise price of 0.6 pence per share.

Application has been made to the London Stock Exchange for the 3,000,000 new Ordinary Shares to be admitted to trading on AIM and admission is expected to occur on or around 8.00am 18 May 2021. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue.

Total Voting Rights

For the purpose of the Disclosure Guidance and Transparency Rules, following the above issue of equity, the issued share capital of the Company will comprise 3,270,722,796 Ordinary Shares. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.

For further information, please contact:

Sareum Holdings plc

Tim Mitchell, CEO

01223 497 700

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

020 7409 3494

Hybridan LLP (Nominated Broker)

Claire Noyce

020 3764 2341

Citigate Dewe Rogerson (Financial PR)

Mark Swallow/ David Dible

020 7638 9571

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

Disclaimer

Sareum Holdings plc published this content on 13 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 May 2021 15:03:04 UTC.


ę Publicnow 2021
All news about SAREUM HOLDINGS PLC
07/30SAREUM : Shares Jump 8% on Incoming Cancer Treatment Patent
MT
07/30SAREUM : Patent Notice of Allowance for SDC-1802
PU
07/21Sareum Holdings plc Provides Financial Guidance for Fiscal 2021
CI
07/19FTSE 100 Closes Down as Covid Cases Rise
DJ
07/19ALAN JOPE : FTSE 100 Slides as Virus Jitters Weigh
DJ
07/19SAREUM : Subscription to raise ú1,000,000
PU
07/01SAREUM : Completed Covid-19 Research Project Delivers Encouraging Results
PU
06/22SAREUM : to Present at BioTrinity 2021 Conference
PU
06/15FTSE 100 Closes Higher Boosted by Strenghtened US Economy
DJ
06/15FTSE Rises, Bellway's Share Price Looks Well Supported
DJ
More news
Financials
Sales 2021 0,17 M 0,23 M 0,23 M
Net income 2021 -1,63 M -2,23 M -2,23 M
Net Debt 2021 - - -
P/E ratio 2021 -1,35x
Yield 2021 -
Capitalization 227 M 311 M 311 M
Capi. / Sales 2021 1 336x
Capi. / Sales 2022 -
Nbr of Employees 6
Free-Float 95,6%
Chart SAREUM HOLDINGS PLC
Duration : Period :
Sareum Holdings plc Technical Analysis Chart | SAR | GB00B02RFS12 | MarketScreener
Technical analysis trends SAREUM HOLDINGS PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,07 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Timothy John Mitchell Chief Executive Officer & Executive Director
Stephen B. Parker Non-Executive Chairman
John Charles Reader Executive Director & Chief Scientific Officer
Clive Birch Independent Non-Executive Director
Michael John Owen Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SAREUM HOLDINGS PLC178.35%311
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
WUXI APPTEC CO., LTD.34.39%68 685
REGENERON PHARMACEUTICALS32.25%66 425
VERTEX PHARMACEUTICALS-22.31%47 634